MBX-4888A shows beneficial additive effect in subacute and chronic TB models

Oct. 17, 2024

Investigators from Microbiotix Inc. have published preclinical data for the novel spectinamide, MBX-4888A (Lee-1810), being developed for the treatment of tuberculosis (TB).

BioWorld Science Infection

Today's news in brief

BioWorld

BioWorld briefs for April 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 7, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Impact of Trump tariffs on med tech proving difficult to anticipate

BioWorld MedTech

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...

Another rebound as Sangamo inks $1.4B capsid deal with Lilly

BioWorld

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an...